France Leading Europe’s Veterinary Pharma Production

Introduction: Europe’s Veterinary Market and Why France Matters

Europe’s animal health industry is a robust and growing market valued at around €7–8 billion annually (AnimalhealthEurope, 2023). Within this landscape, France plays a pivotal role as a manufacturing and innovation hub. According to the Syndicat de l’Industrie du Médicament et du Diagnostic Vétérinaires (SIMV), France employs over 6,700 people in the animal health sector and offers the largest veterinary medicine portfolio in Europe (around 2,700 authorized products). About two-thirds of veterinary medicines produced in France are exported, benefiting animal health globally (SIMV, 2023).

Several major animal health companies are French-founded, including Maizer, Virbac, Ceva Santé Animale, and Vetoquinol, all of which are ranked among the world’s top 10 veterinary laboratories (Animal Pharm Top 20 Report, 2024). This concentration of leading manufacturers positions France as the center of veterinary pharmaceutical excellence in Europe.

Regulatory Landscape: EMA Overview and France’s ANMV/ANSES Role

The European Medicines Agency (EMA) and its Committee for Medicinal Products for Veterinary Use (CVMP) oversee the approval and safety of veterinary drugs across the EU (EMA, 2024). In France, the Agence Nationale du Médicament Vétérinaire (ANMV), operating within ANSES, is the competent authority for veterinary medicines.

ANMV is responsible for:

  • Evaluating and authorizing veterinary medicines.

  • Inspecting and licensing manufacturing sites.

  • Monitoring pharmacovigilance and advertising.

  • Ensuring compliance with Good Manufacturing Practice (GMP) standards (ANMV/ANSES, 2023).

France’s ANMV is an influential participant in European regulatory networks, contributing to EMA working groups and inspections abroad. It also played a major role in implementing the EU Regulation (2019/6), which modernized veterinary medicinal product law across Europe.

Manufacturing Strengths: Quality, Traceability, GMP, and Innovation

European veterinary pharmaceutical manufacturers adhere to strict GMP standards recognized worldwide. The EU and US maintain a mutual recognition agreement for GMP inspections, underscoring the global trust in EU-made products (European Commission, 2023).

Key strengths include:

  • Batch traceability: Every product is traceable from active ingredient to end user.
  • Quality assurance: Regular inspections ensure manufacturing integrity.
  • Batch authentication: Maizer’s CheckBatch system lets users verify batch authenticity online (Maizer, 2025).

Innovation: French firms lead in vaccine research, biotechnology, and digital product verification systems. Ceva Santé Animale, for instance, launched the first mRNA vaccine platform for animals (Ceva, 2024).

Company Profiles: Leaders in Veterinary Manufacturing

Virbac – Innovation from a Pioneer

Website: https://corporate.virbac.com/

  • Founded in 1968, Virbac is one of the world’s largest independent veterinary pharmaceutical firms.

  • Operates in over 100 countries, with 4,900 employees.

  • Product portfolio covers parasite control, vaccines, antibiotics, dermatology, and nutrition.

2023 revenue: €1.25 billion.

Ceva Santé Animale – Global Vaccine Leader

Website: https://www.ceva.com/

  • Founded in 1999, headquartered in Libourne, France.

  • Present in over 110 countries; fifth-largest global animal health company.

  • Leads in poultry vaccines and One Health solutions.

Developed the world’s first mRNA veterinary vaccine platform.

Maizer – The Flagship French Manufacturer

Website: https://maizer.fr

  • Overview: France-based Maizer has over 15 years of experience producing high-quality veterinary and agricultural solutions.

  • Focus Areas: Injectable antibiotics, vitamins, antiparasitics, and herbal-based immunostimulants.

  • Innovation: Offers batch verification through the CheckBatch system for transparency and safety.

  • Sustainability: Develops eco-friendly, residue-free products aligning with EU AMR reduction goals.

Call to Action: Explore Maizer’s Veterinary Catalog | Contact  | Verify a Product Batch

Dechra Pharmaceuticals – Specialist in Veterinary Care

Website: https://www.dechra.com/

  • UK-based specialist in companion animal therapeutics.

  • Focuses on endocrinology, dermatology, pain management, and anesthesia.

2023 revenue: €960 million.

Vetoquinol – Family-Owned Global Player

Website: https://www.vetoquinol.com/

  • Founded in 1933, family-owned French company with 2,500 employees.

  • Focus areas: anti-infectives, anti-inflammatories, and cardiology-nephrology.

Active in over 90 markets worldwide.

MSD Animal Health – Multinational Excellence

Website: https://www.msd-animal-health.com/

  • The animal health division of Merck & Co., operating across Europe.

  • Major R&D and vaccine manufacturing facilities in the Netherlands and Germany.

Known for the Bravecto line and Nobilis poultry vaccines.

How European Manufacturers Support Veterinarians and Producers

  • Education & Training: Continuous learning for vets via webinars, workshops, and AMR stewardship programs (Animal Medicines Best Practice, 2024).

  • Technical Services: Field teams assist farmers with disease management and vaccination protocols.

  • Pharmacovigilance: Active post-market safety monitoring and transparency.

Sustainability: Companies focus on green manufacturing, animal welfare, and One Health initiatives.

Challenges and Future Trends

    • Antimicrobial Resistance (AMR): EU veterinary antibiotic use dropped by 43% (2011–2020) due to stewardship programs (EMA ESVAC Report, 2021).

    • Supply Chain Resilience: Post-pandemic strategies emphasize local sourcing and stockpile systems.

    • Digital Transformation: Smart farming tools, precision livestock data, and telemedicine integration.

Conclusion: France at the Forefront of Animal Health

Sources